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F O R E W O R D
There has been a growing interest in the marine derived bioactivecompounds in the recent years, and the functional foods, enriched
with natural ingredients have been proved to provide beneficial action
for human health. Marine derived bioactive components and the functional food ingredients
demonstrated to possess potential health benefits. High value secondary bioactive
metabolites from the marine organisms are attracting attention because of the growing
demand for new compounds of 'marine natural' origin, having potential applications in
pharmaceutical fields, and concerns about the adverse effects by synthetic drugs and their
derivatives. The pioneering R & D works at ICAR-Central Marine Fisheries Research Institute
on marine bioprospecting envisaged a systematic approach involving chemical profiling of
major species of marine organisms for bioactive pharmacophore leads for activity against
various diseases, and a library of molecules with bioactive potential. The research work in
this institute developed protocols to prepare various pharmaceutical leads, nutraceuticals/
functional food supplements enriched with lead molecules with different properties against
various drug targets for use against various life-threatening diseases.
ICAR-Central Marine Fisheries Research Institute is the pioneering marine research
institute in India to work in the frontier area of bioactive molecule discovery from marine
organisms as promising therapeutic agents against various diseases, aquatic food product
technology, and development of high value products for health management. This prestigious
research institute of Indian Council of Agricultural Research is working in the broad national
interest of producing high value bioactive leads from the marine organisms, which would
provide promising therapeutic agents against various diseases. This institute has developed
and commercialized the nutraceutical products CadalminTM Green Algal extract (CadalminTM
GAe) and Antidiabetic extract (CadalminTM ADe) as green alternatives to synthetic drugs to
combat rheumatic arthritic pains and type-2 diabetes, respectively to a leading
biopharmaceutical company in India. The anti-inflammatory nutraceutical Cadalmin™ Green
Mussel extract (Cadalmin™ GMe) from Asian green mussel Perna viridis has been
commercialized with Amalgam Group of Companies. CadalminTM Antihypercholesterolemic
extract (CadalminTM ACe) has been developed from seaweeds to combat dyslipidemia leading
to obesity, and the product was out-licensed to a leading Indian MNC in wellness and
obesity management. Antimicrobial therapeutic product from marine bacteria as oral
applicant has been developed and the product is in pipeline for commercialization. Seaweed-
derived natural template inspired synthetic derivatives as potential pharmacophores were
designed and developed. Several nutraceutical and cosmeceutical products from marine
organisms are in pipeline, and are being commercialized.
The objective of the National level ICAR Winter School on "Recent advances in bioactive
compounds from marine organisms and development of high-value products for health
management" is to provide up-to-date information and acquaint the participants with the
latest technologies on isolation and characterization of marine natural products of
pharmaceutical importance from marine organisms, general and advanced methods of
isolation procedures by chromatography, classification of organic compounds and their
characterization by advanced spectroscopic experiments. This program further aims to give
exposure to the chemical perspectives of marine organisms, primary and secondary bioactive
metabolites from fish and marine organisms to develop bioactive compounds and high-
value functional food products. Theory and practical classes will be conducted in these
areas to provide the participants a hands-on experience.
This ICAR Winter School is organized with the full funding support from ICAR, New
Delhi, and the twenty-five participants from various parts of India who are attending this
programme were selected after scrutiny of their applications based on their bio-data. They
are serving as academicians, such as Professors/Scientists, and in similar posts. The faculties
include the knowledgeable scientists and professors from various parts of India and abroad.
This training will enable the participants to efficiently carry out their academic programmes,
and to plan research on bioactive molecule discovery in their respective laboratories and
institutes so that they can formulate the strategies for research.
The Winter School on "Recent advances in bioactive compounds from marine organisms
and development of high value products for health management" is very ideal for the
current scenario of increasing lifestyle diseases and human health. Understanding the
importance of natural products in the health care system of India, ICAR-Central Marine
Fisheries Research Institute has reasonably contributed in the various aspects. The Manual
released on this occasion covers all aspects of marine natural products prepared by the
experts in their respective fields. I congratulate the Course Director of this programme, Dr.
Kajal Chakraborty and Head of the Marine Biotechnology Division, Dr. P. Vijayagopal, along
with other staff members of Marine Biotechnology Division and Central Marine Fisheries
Research Institute for their sincere efforts in bringing out the manual in time, and to arrange
the programme in a befitting manner.
A. Gopalakrishnan
Director, ICAR-Central Marine Fisheries Research Institute
Kochi, Kerala
P R E F A C E
Marine-derived bioactive components and the functional food ingredients with potentialhealth benefits are an emerging area of research. The rich diversity of flora and fauna
in the marine and coastal habitats of the Indian subcontinent represent an untapped reservoir
of bioactive compounds with valuable pharmaceutical and biomedical use. Considering the
underutilization of these groups of marine organisms, exploring bioactive compounds and
development of any biologically useful products have benefits as health products.
Comprehensive analyses demonstrated that during the last decade the average proportion
of bioactive compounds among the new compounds is declining, though there are a large
number of marine natural products yet to be explored. This may indicate that the research
level of bioactivity is not keeping up with the discovery of new compounds. Thus, the research
tools and methods for finding bioactivity need to be improved. The first improvement is
about methods of spectral and bioactivity-guided separation and purification of marine-
derived secondary metabolites, which combine the discovery of new compounds. These
improvements in technology are dependent upon the automation in spectroscopy, which
also allows the study of the functions of new compounds extracted from the target marine
organisms. Second, for the discovery of new lead compounds and artificial intelligence for
drug development evolved to a more mechanistic approach that targets specific molecular
lesions. Combined with high-throughput screening through a large number of drug targets,
bioactivity research against various life-threatening diseases will be effective in revealing
the potentially useful biological properties of marine natural products. Furthermore, the
discovery of new bioactive compounds from marine metabolites will form the basis for new
drug leads. Thus, the new compounds will absolutely compose an abundant resource for
future bioactivity research and drug development. Various medicinal and biomedical products
from marine flora and fauna provide a myriad of benefits for human health and multiple
life-threatening diseases, and therefore, are the attractive options for the food and
pharmaceutical industry. The increasing interest in marine-based functional food ingredients
and nutraceutical formulations in the last decade along with increased number of patents
filed/granted have appropriately demonstrated the possibilities of bioactive from marine
organisms to maintain and improve human health and well-being.
The present ICAR Winter School on "Recent advances in bioactive compounds from
marine organisms and development of high-value products for health management" is
designed to acquaint the participants with the advances in marine bioactive compounds
with emphasis on the latest technologies on isolation and characterization of marine natural
products of pharmaceutical importance. The course is planned in such a way that it covers
both theoretical and practical aspect of recent advances in bioactive compounds from marine
organisms. This programme will strengthen the knowledge of participants with regard to
the general and advanced methods of isolation procedures by chromatography, and their
characterization by advanced spectroscopic experiments aspects.
I wish to thank the Education Division of Indian Council of Agricultural Research for
giving us an opportunity to organize this ICAR Winter School. We are grateful to Dr. A.
Gopalakrishnan, Director, ICAR-Central Marine Fisheries Research Institute, for his guidance,
continuous interest in the course and providing all necessary facilities. I am highly obliged
to Dr. P. Vijayagopal, Head, Marine Biotechnology Division for his guidance and support for
the programme. All the scientists of Marine Biotechnology Division, technical staff, supporting
staff and research scholars supported us in organizing the ICAR Winter School. I recall with
gratitude the marvellous effort and help in preparing this manual by Minju Joy, Research
Scholar of Marine Biotechnology Division. I take this opportunity to thank all the faculty
members who have devoted their valuable time and contributed material for the preparation
of the manual. I am confident that the Course Manual would aid the participants to enhance
their knowledge and competence in the area of marine bioactive compounds and their
applications for the development of high-value products for health management.
Kajal Chakraborty
January, 2018 Course Director
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Bioactive marine natural products
For thousands of year’s natural products have played a key role in the development of
cures for diseases.  Extensive literature reviews by Gordon Cragg and David Newman of the
U.S. National Institutes of Health and others have shown that over 60% of all drugs sold in
the market are of natural products origin. In the area of cancer chemotherapy this figure is
close to 67%. Even though many of these are of terrestrial plant or microbiological origin,
marine organisms have become targets of drug discovery efforts since 1960’s. With the
advent of SCUBA and availability of sophisticated separation and structure elucidation
technologies the field of marine natural products has blossomed in the past few decades,
WHY MARINE NATURAL PRODUCTS?
The marine flora and fauna remain largely unexplored. Approximately 71% of the
molecular entities listed in the Dictionary of Marine Natural Products have novel molecular
structures compared to ~40% of those in the Dictionary of Natural Products. In NCI preclinical
cytotoxicity screen, marine organisms show higher incidence of anti-tumor potential: 1%
vs. 0.1% for terrestrial organisms. Number of new marine compounds reported each year is
increasing >1000 compounds.
EXAMPLES OF PROMINENT GROUPS OF MARINE NATURAL PRODUCT DRUGS
Ara C, Ara A, and AZT
Ara C is an anti-leukemic agents sold by Pharmacia (formerly Upjohn) and Glaxo
SmithKline as Cytosar-U. Ara A (vidarabine) was a drug sold in the US and elsewhere as an
antiviral agent. AZT, is the first effective drug against AIDS. These were designed based on
the discovery of spongothymidine and spongouridine isolated from the Caribbean sponge
Tethya crypta by Bergmann in 1950’s.
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ù-Conotoxin
ù-Conotoxin MVIIA was first isolated in 1979 by Oilvera and co-workers from the Pacific
piscivorous marine snail Conus magus. It is a linear 25 amino acid, polycationic peptide
containing six cysteine residues linked by three disulfide bridges that stabilize its well-defined
three dimensional structures. It inhibits N-type voltage-dependent calcium channels – 1000
times more powerful than morphine. Its complete chemical synthesis was achieved in 1987.
After more than two decades of research and development, ziconotide, a synthetic form of
ù-conotoxin MVIIA under the trade name Prialt, is being used for the specific indication of
chronic pain.
Trabectedin - Ecteinascidin 743
Originally isolated from Ecteinascidia turbinata in 1969 by A.J. Weinheimer et al. E.
turbinata is a mangrove tunicate, a colonial ascidian. Structure was elucidated in 1990
independently by Ken Rinehart et al. of Illinois and Amy Wright et al. of Harbor Branch
Oceanographic Institution, Florida. Sold by Zeltia and Johnson and Johnson under the brand
name Yondelis. Approved for use in Europe and South Korea for the treatment of advanced
soft tissue sarcoma and relapsed ovarian cancers. Undergoing clinical trials for the treatment
of breast, prostate, and pediatric sarcoma - cancer that begins
in the muscle, fat, fibrous tissue, blood vessels, or other
supporting soft tissues of the body. US FDA approved the
drug in 2015 for soft tissue sarcomas - liposarcoma and
leiomyosarcoma.
PM01183 (Lurbinectedin)
An analog of trabectidin is undergoing Phase III clinical
evaluations against metastatic breast cancer. It was isolated
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from symbiotic microbacteria growing on the tunicate. Drug is being developed by ParmaMar,
S.A. It blocks trans-activated transcription, induces DNA double-strand breaks and modulates
tumor microenvironment.
Jorumycin (Zalypsis)
Isolated from nudibranch Jorunna funebris collected in India by Fontana et al. in 2000.
Developed by Pharmamar as a treatment for lung and colon cancer as well as melanoma.
Structurally related to ecteinascidin 743
Halichondrin B
One of a series of compounds originally isolated in the 1980’s from Halichondria okadai
and subsequently from other sponges, including Lissodendoryx sp. Synthesized by Professor
Kishi of Harvard University and the synthetic analog (eribulin mesylate) produced by Eisai
Research Institute  (MA) is an FDA approved as a drug against advanced or metastatic
breast cancer previously treated with anthracyclines and taxanes.
Eribulin Mesylate
The FDA approved the microtubule inhibitor Halaven,®
eribulin mesylate, a derivative of halichondrin to treat metastatic
breast cancer. It essentially contains the macrocyclic ring
portion. It acts by a novel microtubule targeting mechanism
where it aggregates tubulin and selectively blocks microtubule
growth and inhibits mitosis.
Recent advances in bioactive compounds from marine organisms and development of high value products
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Didemnin B
Isolated from Carbbean tunicate Trididemnum solidum by late Professor Ken Rinehart
of Univ. of Illinois. Displayed antiviral and in vivo cytotoxic activities at nanomolar
concentrations. Reached Phase II clinical trials against cancer. Did not make it to Phase III
because of its toxicity.
Aplidine (Plitidepsin)
Extracted from the ascidian Aplidium albicans by Rinehart group. Differs from didemnin
B only in replacement of the N-lactyl side chain with a pyruvyl group. Pharmamar (Spanish
company) is conducting a randomized, multicenter, open-label, Phase III study of plitidepsin
in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/
refractory multiple myeloma. Has been given orphan drug status by WHO
HTI-286 - A Hemiasterlin derivative
Hemiasterlin, a cytotoxic peptide was first isolated from S. African sponge Hemiasterella
minor by Y. Kashman et al., (Tel Aviv) in 1994. Related isomers hemiasterlin A & B, were
reported by Raymond Andersen and co-
workers from sponges of the genus
Auletta and Cymbastella in 1995. HTI-286
is a synthetic analog made by Anderson
and Wyeth labs - their partner in an NIH
supported research program. Work by E.
Hamel (2008 Nobel Laureate) showed
that it interacts with tubulin to produce microtubule depolymerization similar to vinblastine.
Unfortunately it was withdrawn from further development during phase-II clinical trials for
the treatment of non-small cell lung cancer
Dolastatin 10
Cytotoxic peptide from Indian Ocean mollusk Dolabella auricularia by Prof. George
Pettit of University of Arizona. Underwent Phase II trials against metastatic or recurrent liver,
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bile duct, colorectal, gallbladder, and prostate ancer but is not move on to the next phase.
Dolastatin 10 exhibited a unique interaction with tubulin. Three other dolastatin derivatives
are also currently progressing through clinical trials as a single agent against prostate
adenocarcinoma188, NSCLC 189, melanoma 190, colorectal cancer 191, soft-tissue sarcomas
192, breast cancer 193, and pancreatic cancer.
Cryptophycins
Derived from filamentous blue-green alga (cyanobacterium) by late Richard Moore of
University of Hawaii. A synthetic analogue of Crp-1, cryptophycin-52 was developed by Eli
lilly to improve hydrolytic stability and formulation. Underwent clinical trials against non-
small cell lung cancer (NSCLC) with advanced tumor but was withdrawn. However, new
analogs cryptophycin-309 and cryptophycin-249, have undergone preclinical efficacy studies
and may soon enter clinical trials.
Spongistatin
z Derived from a marine sponge Spirastrella spinispirulifera species from Eastern
Indian Ocean near Maldives.
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z Extremely potent activity against selected human tumor cell types in the U.S.
National Cancer Institute’s primary screen.
z Inhibits mitosis by binding in the Vinca alkaloid domain of tubulin thus preventing
tubulin assembly.
z Being tried in combination with vincristine as potential anticancer agent.
Discodermolide
z Isolated by Harbor Branch chemist and my friend, Dr. Sarath Gunasakera from the
deep water Caribbean sponge Discodermia dissoluta.
z Initially was found have immunosuppressive property but subsequently found to
have stronger tubulin binding property than Taxol.
z Effective in paclitaxel and in epothilone-resistant cancer cells.
z Underwent clinical trials as an
antitumor agent against
colorectal cancers but dropped
after Phase I clinical trials due
to toxicity.
z Analogs are being looked at
and combination therapy with
paclitaxel is also a possibility.
At this point it might be important to give an overview of the drug development process,
especially the clinical trials. These are carried out after the pre-clinical development work
that includes animal testing to evaluate toxicity, pharmacology and pharmacokinetics.
Typically, formulation and stability studies are also carried out in parallel. The formulated
drug candidate is used in clinical trials.
CLINICAL TRIALS
z Phase I trials are the first stage of testing in human subjects.
– Normally, a small (20-100) group of healthy volunteers will be selected.
– Designed to assess the safety (pharmacovigilance), tolerability,
pharmacokinetics, and pharmacodynamics of a drug
– Often conducted in an inpatient clinic, where the subject can be observed
by full-time staff.
– Phase I trials most often include healthy volunteers.
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– In some circumstances real patients are used, such as patients who have
end-stage disease and lack other treatment options
– Volunteers are paid for their inconvenience
z Phase II
– performed on larger groups (20-300) and are designed to assess how well
the drug works
– development process for a new drug often fails during Phase II trials when
the drug is discovered not to work as planned, or to have toxic effects.
– Phase II studies are sometimes divided into Phase IIA and Phase IIB.
z Phase IIA is specifically designed to assess dosing requirements (how much drug
should be given),
z Phase IIB is specifically designed to study efficacy (how well the drug works at the
prescribed dose(s)).
– Some trials combine Phase I and Phase II, and test both efficacy and toxicity.
z Phase III studies are randomized controlled multicenter trials on large patient
groups - 300-3,000 or more depending upon the disease/medical condition studied
– Aimed at being the definitive assessment of how effective the drug is, in
comparison with current treatments.
– Because of their size and comparatively long duration, Phase III trials are the
most expensive, time-consuming and difficult trials to design and run,
especially in therapies for chronic medical conditions.
– Most drugs undergoing Phase III clinical trials can be marketed under FDA
norms with proper recommendations and guidelines, but in case of any
adverse effects being reported anywhere, the drugs need to be recalled
immediately from the market.
z Phase III studies are randomized controlled multicenter trials on large patient
groups - 300-3,000 or more depending upon the disease/medical condition studied
z Aimed at being the definitive assessment of how effective the drug is, in
comparison with current treatments.
z Because of their size and comparatively long duration, Phase III trials are the
most expensive, time-consuming and difficult trials to design and run,
especially in therapies for chronic medical conditions.
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– Most drugs undergoing Phase III clinical trials can be marketed under FDA
norms with proper recommendations and guidelines, but in case of any
adverse effects being reported anywhere, the drugs need to be recalled
immediately from the market.
z Phase IV studies (aka post marketing surveillance trials) are conducted after a
drug has been approved for consumer sale
z The objectives include:
– to compare a drug with other drugs already in the market
– to monitor a drug’s long-term effectiveness and impact on a patient’s quality
of life
– to determine the cost-effectiveness of a drug therapy relative to other
traditional and new therapies.
z Phase IV studies could result in a drug being taken off the market or
restrictions of use could be placed on the product.
Auristatin Derivatives
Currently, over 78 antibody drug conjugates (ADCs) are in clinical trials and employ
auristatins as warheads (payloads). One such study has led to the U.S. FDA approval of ADC,
brentuximab vedotin (Adcetris®, Seattle Genetics) to treat relapsed or refractory Hodgkin
lymphoma and systemic anaplastic large cell lymphoma.  It was earlier approved by European
Medicine Agency and in Japan. It contains monomethyl auristatin E (MMAE)
Auristatins in Clinical Trials
Newman and Cragg reports that as of March 2017, the following auristatin containing
ADC’s are being studied.
– Phase III: seven (six being directed against various lymphomas with multiple
drug regimens, and one being a comparative trial).
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– Phase II: 53 (52 against various lymphomas with 15 only studying brentuximab
vedotin, 35 having a variety of other drug treatments in addition to the
ADC, and one where the ADC alone is being tested against mesothelioma).
– Phase I: 28 (27 against lymphomas and leukemias, with one against mycosis
fungoides/Sezary Syndrome. One trial has brentuximab vedotin as the sole
agent studying Graft versus Host Disease following allogenic stem cell
transplantation).
Bryostatins
z Bryostatins were isolated from the bryozoan, Bugula neritina, by Pettit group. Many
analogs have been isolated.
z It was one of the promising marine natural products.
z Bryostatin 1 went through Phase II clinical trials as an anticancer agent but did not
proceed into Phase III due to adverse side effects.
z As of 2013 it was being tested in Phase II clinical trials as a treatment for Alzheimer’s
disease.
Kahalalide
z Cyclic depsipeptide isolated by Prof. Paul Scheuer’s group at U. of Hawaii from the
sacoglassan mollusk Elysia rufescens – apparently comes from the alga Bryopsis
sp. on which it grazes.
z Kahalalide F (KF) is the largest and the most biologically active of the 13 natural
peptides isolated from E. rufescens.
z KF was subsequently synthesized by Spanish researchers using peptide synthesis
methodology.
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z KF is being evaluated in phase II clinical trials for the treatment of prostate, breast
and liver cancers.
Elisidepsin - A Kahalalide F derivative
z Elisidepsin (Irvalec®) is a synthetic cyclic
analog of kahalalide F.
z Currently in phase II clinical trials in patients
with advanced/metastatic non-small cell lung,
esophageal and gastric cancers.
Plinabulin
z Plinabulin is a small molecule under development by BeyondSpring
Pharmaceuticals, and is in a world-wide Phase III clinical trial for non-small cell
lung cancer.
z A synthetic analogue of the diketipiperazine phenylahistin, a natural product
isolated from a marine and terrestrial fungus, Aspergillus sp.
z It selectively binds to the colchicine-binding site of tubulin. This disrupts mitotic
spindle assembly leading to cell cycle arrest at M phase and blockage of cell division.
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Squalamine
z Simple amino sterol isolated from a dogfish shark, Squalus acanthias, collected off
New England coast.
z Undergoing Phase II clinical trials against ovarian cancer, NSCLC, and prostate
cancer.
z Squalamine exhibits anti-angiogenic activity under certain conditions (angiogenesis
is the formation and differentiation of blood vessels).
Salinosporamide A
z A potent proteasome inhibitor isolated from the marine bacteria Salinispora tropica
and Salinispora arenicola, which are found in ocean sediment.
z Has been given orphan drug approval (Marizomib) for the treatment of multiple
myeloma and being evaluated as treatment for other cancers.
z Possess a highly functionalized ã-lactam-â-lactone bicyclic core. Unique activity -
irreversibly inhibits the three major catalytic activities of the 20S core of the
ubiquitin-26S proteasome.
z Scripps Institute scientists
led by Fenical and Moore
have sequenced the
5,183,331 bp genome and
analyzed all identifiable
gene clusters to establish
the biosynthetic pathways
for the metabolites.
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Pseudopterosins
z Pseudopterosins are a group of diterpene glycosides primarily extracted from the
octocoral of the genus Pseudopterogorgia.
z They possess an array of potent biological activities including anti-inflammatory
and analgesic, wound-healing, anti-bacterial, anti-cancer, anti-viral, anti-malarial,
and anti-tuberculosis in both in vitro and in vivo assays with a novel mechanism of
action.
z In Phase II clinical trials, pseudopterosins were found to augment re-epithelialization
process with qualitative enhancement in the early wound repair process.
z Pseudopterosins are now a constituent of the cosmetic “anti-wrinkle cream” sold
by Estee Lauder under the brand name “Resilience.”
Compounds undergoing pre-clinical evaluation
z Salicylhalimide from the Western Australian sponge Haliclona sp.
– Potential antitumor agent as well as use as bone resorption agent
z Thiocoraline from an actinomcyete (rod-shaped gram positive bacteria)
– Showed potential as an anticancer agent in NCI 60-cell line screen
– Inhibits DNA polymerase a
z Dictyodendrins from Japanese sponge Dictyodendrilla verongiformis
– telomerase inhibitors for potential treatment against Alzheimer’s disease
DMBX-A (GTS-21) - A possible treatment Alzheimer’s disease
z A synthetic derivative of naturally occurring anabaseine derived from a marine
worm, Amphiporus lactifloreus
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z 3-(2,4-Dimethoxybenzylidene)-anabaseine (DMXBA; also called GTS-21), is an
alpha7 acetylcholine receptor (á7AChR) agonist.
z Undergoing Phase II clinical trials for the treatment of Anzheimer’s disease as well
as schizophrenia
CONCLUSIONS
The field of marine natural products continues to flourish as seen by the number papers
published despite the diminished financial support by pharmaceutical companies.  Most of
the major multinational phama companies dropped their natural products drug discovery
sections in the 1990’s and 2000’s but governmental support in the US continued for the
most part until this decade. The focus has been shifting from traditional bioassay-guided
separations followed by structure determination to novel dereplication methods using the
power of LC-MS, MS-MS, and the emerging technology of LC-NMR. Molecular biology and
metabolomics are also beginning to emerge as a tool to discover and produce natural
products of interest.  As stated by Newman et al. in their 2010 article in Cell Press. Opinions
from leaders in the field of marine natural products all agree that the potential of these
compounds to significantly contribute to the pharmacopeiais still on the horizon. With the
eminent development of more marine natural products from those in the current pipeline,
the contribution of marine natural products to the future pharmacopeia seems to be
promising. New technologies and efficient collaborations between academic and industrial
scientists will be essential to ensure the future success of marine natural products as new
and novel therapeutic entities that can make a significant contribution to the treatment of
human disease.”
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